Gojo: Abbvie: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Jazz: Consultancy, Honoraria; Amphivena: Research Funding; Amgen Inc: Consultancy, Honoraria, Research Funding; Juno: Research Funding; Merck: Research Funding. Webster:Pfizer: Consultancy; Amgen: Consultancy; Genentech: Research Funding. Varela:Alexion: Speakers Bureau; NexImmune: Equity Ownership, Membership on an entity's Board of Directors or advisory committees. DeZern:Astex Pharmaceuticals, Inc.: Consultancy; Celgene: Consultancy. Foster:Bellicum Pharmaceuticals, Inc: Research Funding; MacroGenics: Research Funding; Celgene: Research Funding; Daiichi Sankyo: Consultancy. Levis:Astellas: Consultancy, Research Funding; FUJIFILM: Consultancy, Research Funding; Menarini: Consultancy, Honoraria; Novartis: Consultancy, Research Funding; Agios: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Daiichi Sankyo Inc: Consultancy, Honoraria. Coombs:Abbvie: Consultancy; Covance: Consultancy; Pharmacyclics: Honoraria; Cowen & Co.: Consultancy; Medscape: Honoraria; Octopharma: Honoraria; H3 Biomedicine: Honoraria; Loxo: Honoraria; Dedham Group: Consultancy. Smith:Novartis: Consultancy; Agios: Consultancy; Pfizer: Consultancy; Jazz: Consultancy; Celgene: Consultancy. Vincent:Merck: Research Funding; Pharmacyclics: Research Funding. Serody:Merck: Research Funding; GlaxoSmithKline: Research Funding. Luznik:AbbVie: Consultancy; WindMiL Therapeutics: Patents & Royalties: Patent holder; Merck: Research Funding, Speakers Bureau; Genentech: Research Funding. Zeidner:Tolero: Honoraria, Research Funding; Pfizer: Honoraria; AsystBio Laboratories: Consultancy; Daiichi Sankyo: Honoraria; Celgene: Consultancy, Honoraria, Research Funding; Agios: Honoraria; Merck: Research Funding; Takeda: Research Funding; AbbVie: Honoraria.Pembroluzimab - a PD1 checkpoint inhibitor which is not approved in AML (off-label drug use)